A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers
- Conditions
- Advanced Solid Tumors
- Interventions
- Drug: Platinum-based doublet chemotherapyDrug: Trifluridine-tipiracil
- Registration Number
- NCT04626635
- Lead Sponsor
- Regeneron Pharmaceuticals
- Brief Summary
This study is researching an investigational drug called REGN7075 by itself and in combination with cemiplimab with or without chemotherapy. The study is focused on patients with certain solid tumors that are in an advanced stage. The aim of the study is to see how safe and tolerable REGN7075 is by itself and in combination with cemiplimab (with or without chemotherapy), and to find out what is the best dose of REGN7075 to be given to patients with advanced solid tumors when combined with cemiplimab (with or without chemotherapy). Another aim of the study is to see how effective REGN7075 by itself, or in combination with cemiplimab (with or without chemotherapy), is at treating cancer patients.
The study is also looking at:
* Side effects that may be experienced by people taking REGN7075 by itself and in combination with cemiplimab with or without chemotherapy
* How REGN7075 works in the body by itself and in combination with cemiplimab with or without chemotherapy
* How much REGN7075 is present in the blood when given by itself and in combination with cemiplimab with or without chemotherapy
* To see if REGN7075 by itself and in combination with cemiplimab with or without chemotherapy works to treat cancer by controlling the proliferation of tumor cells to shrink the tumor
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 933
- Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Has histologically or cytologically confirmed cancer that meets criteria as defined in the protocol
- Expansion Cohorts only: Is anti-programmed cell death protein-1 (PD-1)/programmed cell death ligand-1 (PD-L1) naïve, defined as never having previously been treated with a drug that targets the PD-1
- Has at least 1 lesion that meets study criteria as defined in the protocol
- Willing to provide tumor tissue from newly obtained biopsy (at a minimum core biopsy) from a tumor site that has not been previously irradiated
- Has adequate organ and bone marrow function as defined in the protocol
- In the judgement of the investigator, has a life expectancy of at least 3 months
Key
- Is currently participating in another study of a therapeutic agent
- Has participated in any study of an investigational agent or an investigational device within 4 weeks of the first administration of study drug as defined in the protocol
- Has received treatment with an approved systemic therapy within 4 weeks of the first administration of study drug or has not yet recovered (ie, grade 1 or baseline) from any acute toxicities
- Has received recent anti-epidermal growth factor receptor (EGFR) antibody therapy as defined in the protocol
- Has received radiation therapy or major surgery within 14 days of the first administration of study drug or has not recovered (ie, grade 1 or baseline) from adverse events
- Has received any previous systemic, non-immunomodulatory biologic therapy within 4 weeks of first administration of study drug.
- Has had prior anti-cancer immunotherapy within 5 half-lives prior to study drug as defined in the protocol
- Has second malignancy that is progressing or requires active treatment as defined in the protocol
- Has any condition requiring ongoing/continuous corticosteroid therapy (>10 mg prednisone/day or anti-inflammatory equivalent) within 1-2 weeks prior to the first dose of study drug as defined in the protocol
- Has ongoing or recent (within 5 years) evidence of significant autoimmune disease or any other condition that required treatment with systemic immunosuppressive treatments as defined in the protocol
- Has untreated or active primary brain tumor, CNS metastases, leptomeningeal disease, or spinal cord compression
- Has encephalitis, meningitis, organic brain disease (eg, Parkinson's disease) or uncontrolled seizures within 1 year prior to the first dose of study drug
- Has any ongoing inflammatory skin disease as defined in the protocol
NOTE: Other protocol-defined Inclusion/ Exclusion Criteria apply
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SEQUENTIAL
- Arm && Interventions
Group Intervention Description Dose Escalation Cemiplimab Variety of mixed advanced solid tumor types Dose Expansion A Cemiplimab Triple Negative Breast Cancer (TNBC) Dose Expansion B Cemiplimab Cutaneous Squamous Cell Carcinoma (CSCC) Dose Expansion C Cemiplimab Non-Small Cell Lung Cancer (NSCLC) Dose Expansion D Cemiplimab Head and Neck Squamous Cell Carcinoma (HNSCC) Dose Expansion E Cemiplimab Microsatellite Stable-Colorectal Cancer (MSS-CRC), with Active Liver Metastases and/or Active Peritoneal Metastases Dose Expansion F Cemiplimab MSS-CRC with Isolated Lung/Lymph Node Metastases (no active liver and no active peritoneal metastases) Dose Expansion G Cemiplimab Epidermal Growth Factor Receptor (EGFR) -mutant NSCLC Post Third Generation tyrosine kinase inhibitor (TKI) Dose Expansion H Cemiplimab EGFR-mutant NSCLC Post Third Generation TKI and Post Platinum-Doublet Chemotherapy Dose Expansion I Cemiplimab Third-line (3L) MSS-CRC with Active Liver Metastases Dose Expansion J Cemiplimab 3L MSS-CRC without Active Liver Metastases Dose Expansion H REGN7075 EGFR-mutant NSCLC Post Third Generation TKI and Post Platinum-Doublet Chemotherapy Dose Expansion C Platinum-based doublet chemotherapy Non-Small Cell Lung Cancer (NSCLC) Dose Expansion D REGN7075 Head and Neck Squamous Cell Carcinoma (HNSCC) Dose Expansion E REGN7075 Microsatellite Stable-Colorectal Cancer (MSS-CRC), with Active Liver Metastases and/or Active Peritoneal Metastases Dose Expansion I Trifluridine-tipiracil Third-line (3L) MSS-CRC with Active Liver Metastases Dose Expansion J REGN7075 3L MSS-CRC without Active Liver Metastases Dose Expansion J Bevacizumab 3L MSS-CRC without Active Liver Metastases Dose Expansion J Trifluridine-tipiracil 3L MSS-CRC without Active Liver Metastases Dose Escalation REGN7075 Variety of mixed advanced solid tumor types Dose Expansion A REGN7075 Triple Negative Breast Cancer (TNBC) Dose Expansion B REGN7075 Cutaneous Squamous Cell Carcinoma (CSCC) Dose Expansion C REGN7075 Non-Small Cell Lung Cancer (NSCLC) Dose Expansion F REGN7075 MSS-CRC with Isolated Lung/Lymph Node Metastases (no active liver and no active peritoneal metastases) Dose Expansion G REGN7075 Epidermal Growth Factor Receptor (EGFR) -mutant NSCLC Post Third Generation tyrosine kinase inhibitor (TKI) Dose Expansion G Platinum-based doublet chemotherapy Epidermal Growth Factor Receptor (EGFR) -mutant NSCLC Post Third Generation tyrosine kinase inhibitor (TKI) Dose Expansion I REGN7075 Third-line (3L) MSS-CRC with Active Liver Metastases Dose Expansion I Bevacizumab Third-line (3L) MSS-CRC with Active Liver Metastases
- Primary Outcome Measures
Name Time Method The incidence of dose-limiting toxicities (DLTs) during the DLT period Up to 6 weeks Dose escalation
Incidence and severity of treatment-emergent adverse events (TEAEs) Approximately 90 days from last dose; up to 5 years Dose escalation
Incidence and severity of adverse events of special interest (AESIs) Approximately 90 days from last dose; up to 5 years Dose escalation
Incidence and severity of serious adverse events (SAEs) Approximately 90 days from last dose; up to 5 years Dose escalation
Incidence and severity of grade ≥3 laboratory abnormalities Approximately 90 days from last dose; up to 5 years Dose escalation
Objective Response Rate (ORR) Up to 5 years Dose expansion
- Secondary Outcome Measures
Name Time Method Concentrations of REGN7075 in serum Up to 5 years Dose escalation and dose expansion
Incidence of anti-drug antibodies (ADA) to REGN7075 Approximately 90 days from last dose; up to 5 years Dose escalation and dose expansion
The incidence and severity of AESIs Approximately 90 days from last dose; up to 5 years Dose expansion
Progression free survival (PFS) Up to 5 years Dose escalation and dose expansion
Titers of ADA to cemiplimab Approximately 90 days from last dose; up to 5 years Dose escalation and dose expansion
Patient reported Quality of Life (QoL) per EORTC QLQ-BR23 in breast cancer patients Approximately 90 days from last dose; up to 5 years The EORTC-QLQ-BR23 includes functional scales (body image, sexual functioning, sexual enjoyment, and future perspective) and single item symptoms scales (systemic therapy side effects, breast symptoms, arm symptoms, and upset by hair loss). Questions use 4-point Likert scale (1 'Not at All' to 4 'Very Much'). Scores average and transformed to 0-100 scale. High score for functional scale=high/healthy level of functioning. High score for single item=high level of symptomatology/problems.
Patient reported symptoms per EORTC QLQ-BR23 in breast cancer patients Approximately 90 days from last dose; up to 5 years The EORTC-QLQ-BR23 includes functional scales (body image, sexual functioning, sexual enjoyment, and future perspective) and single item symptoms scales (systemic therapy side effects, breast symptoms, arm symptoms, and upset by hair loss). Questions use 4-point Likert scale (1 'Not at All' to 4 'Very Much'). Scores average and transformed to 0-100 scale. High score for functional scale=high/healthy level of functioning. High score for single item=high level of symptomatology/problems.
Patient reported symptoms per EQ-5D-5L Approximately 90 days from last dose; up to 5 years The EQ-5D-5L consists of EQ-5D descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems.
Disease control rate (DCR) Up to 5 years Dose escalation and dose expansion
Overall survival (OS) Up to 5 years Dose escalation and dose expansion
Incidence of ADA to cemiplimab Approximately 90 days from last dose; up to 5 years Dose escalation and dose expansion
The incidence and severity of TEAEs Approximately 90 days from last dose; up to 5 years Dose expansion
The incidence and severity of SAEs Approximately 90 days from last dose; up to 5 years Dose expansion
Patient reported Quality of Life (QoL) per EQ-5D-5L Approximately 90 days from last dose; up to 5 years The EQ-5D-5L consists of EQ-5D descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems.
Patient reported symptoms per EORTC QLQ-C30 Approximately 90 days from last dose; up to 5 years EORTC-QLQ-C30 is a 30-item subject self-report questionnaire composed of both multi-item and single scales, including a global health status/quality of life (GHS/QoL) scale. Participants rate items on a four-point scale, with 1 as "not at all" and 4 as "very much." A change of 5 - 10 points is considered a small change. A change of 10 - 20 points is considered a moderate change.
Patient reported functioning per EORTC QLQ-LC13 in NSCLC patients Approximately 90 days from last dose; up to 5 years The EORTC QLQ-LC13 is a 13-item, disease-specific module which assesses quality of life across multiple scales, including dyspnea, cough and chest pain.
The scale for EORTC-QLQ-LC13 is 1-4 for most outcome measures of systems, with 1 rated as "not at all" and 4 rated as "very much".Patient reported Quality of Life (QoL) per EORTC QLQ-C30 Approximately 90 days from last dose; up to 5 years EORTC-QLQ-C30 is a 30-item subject self-report questionnaire composed of both multi-item and single scales, including a global health status/quality of life (GHS/QoL) scale. Participants rate items on a four-point scale, with 1 as "not at all" and 4 as "very much." A change of 5 - 10 points is considered a small change. A change of 10 - 20 points is considered a moderate change.
ORR Up to 5 years Dose escalation
Duration of Response (DOR) Up to 5 years Dose escalation and dose expansion
Complete response (CR) rate Up to 5 years Dose escalation and dose expansion
Titers of ADA to REGN7075 Approximately 90 days from last dose; up to 5 years Dose escalation and dose expansion
Patient reported Quality of Life (QoL) per EORTC QLQ-CR29 in CRC patients Approximately 90 days from last dose; up to 5 years The EORTC QLQ CR-29 questionnaire consists of 29 items (Likert scale), with a response scale for each of them from 1 to 4, with the following structure: 1 = Not at All 2 = A little; 3 = Quite a Bit; 4 = Very much. The QLQ-CR29 has five functional and 18 symptom scales. It contains four subscales (urinary frequency (UF), blood and mucus in stool (BMS), stool frequency (SF), and body image (BI)) and 19 single items (urinary incontinence, dysuria, abdominal pain, buttock pain, bloating, dry mouth, hair loss, taste, anxiety, weight, flatulence, fecal incontinence, sore skin, embarrassment, stoma care problems, sexual interest (men), impotence, sexual interest (women), and dyspareunia). Scores can be linearly transformed to provide a score from 0 to 100. Higher scores represent better functioning on the functional scales and a higher level of symptoms on the symptom scales.
Patient reported symptoms per EORTC QLQ-HN35 in HNSCC patients Approximately 90 days from last dose; up to 5 years The EORTC QLQ-HN35 is a 35-item, disease-specific module which assesses quality of life across multiple scales, including pain, swallowing, and senses.
The questionnaire has 35 Likert type questions in total and the evaluation is made by giving the score of None: 1, A little: 2, Quite: 3, A lot: 4.Patient reported functioning per EORTC QLQ-BR23 in breast cancer patients Approximately 90 days from last dose; up to 5 years The EORTC-QLQ-BR23 includes functional scales (body image, sexual functioning, sexual enjoyment, and future perspective) and single item symptoms scales (systemic therapy side effects, breast symptoms, arm symptoms, and upset by hair loss). Questions use 4-point Likert scale (1 'Not at All' to 4 'Very Much'). Scores average and transformed to 0-100 scale. High score for functional scale=high/healthy level of functioning. High score for single item=high level of symptomatology/problems.
The incidence and severity of grade ≥3 laboratory abnormalities Approximately 90 days from last dose; up to 5 years Dose expansion
Patient reported Quality of Life (QoL) per EORTC QLQ-HN35 in HNSCC patients Approximately 90 days from last dose; up to 5 years The EORTC QLQ-HN35 is a 35-item, disease-specific module which assesses quality of life across multiple scales, including pain, swallowing, and senses.
The questionnaire has 35 Likert type questions in total and the evaluation is made by giving the score of None: 1, A little: 2, Quite: 3, A lot: 4.Patient reported symptoms per EORTC QLQ-LC13 in NSCLC patients Approximately 90 days from last dose; up to 5 years The EORTC QLQ-LC13 is a 13-item, disease-specific module which assesses quality of life across multiple scales, including dyspnea, cough and chest pain.
The scale for EORTC-QLQ-LC13 is 1-4 for most outcome measures of systems, with 1 rated as "not at all" and 4 rated as "very much".Patient reporting general health status per EORTC QLQ-LC13 in NSCLC patients Approximately 90 days from last dose; up to 5 years The EORTC QLQ-LC13 is a 13-item, disease-specific module which assesses quality of life across multiple scales, including dyspnea, cough and chest pain.
The scale for EORTC-QLQ-LC13 is 1-4 for most outcome measures of systems, with 1 rated as "not at all" and 4 rated as "very much".Patient reporting general health status per EORTC QLQ-HN35 in HNSCC patients Approximately 90 days from last dose; up to 5 years The EORTC QLQ-HN35 is a 35-item, disease-specific module which assesses quality of life across multiple scales, including pain, swallowing, and senses.
The questionnaire has 35 Likert type questions in total and the evaluation is made by giving the score of None: 1, A little: 2, Quite: 3, A lot: 4.Patient reported Quality of Life (QoL) per EORTC QLQ-LC13 in NSCLC patients Approximately 90 days from last dose; up to 5 years The EORTC QLQ-LC13 is a 13-item, disease-specific module which assesses quality of life across multiple scales, including dyspnea, cough and chest pain.
The scale for EORTC-QLQ-LC13 is 1-4 for most outcome measures of systems, with 1 rated as "not at all" and 4 rated as "very much".Patient reported symptoms per EORTC QLQ-CR29 in CRC patients Approximately 90 days from last dose; up to 5 years The EORTC QLQ CR-29 questionnaire consists of 29 items (Likert scale), with a response scale for each of them from 1 to 4, with the following structure: 1 = Not at All 2 = A little; 3 = Quite a Bit; 4 = Very much. The QLQ-CR29 has five functional and 18 symptom scales. It contains four subscales (urinary frequency (UF), blood and mucus in stool (BMS), stool frequency (SF), and body image (BI)) and 19 single items (urinary incontinence, dysuria, abdominal pain, buttock pain, bloating, dry mouth, hair loss, taste, anxiety, weight, flatulence, fecal incontinence, sore skin, embarrassment, stoma care problems, sexual interest (men), impotence, sexual interest (women), and dyspareunia). . Scores can be linearly transformed to provide a score from 0 to 100. Higher scores represent better functioning on the functional scales and a higher level of symptoms on the symptom scales.
Patient reported functioning per EORTC QLQ-C30 Approximately 90 days from last dose; up to 5 years EORTC-QLQ-C30 is a 30-item subject self-report questionnaire composed of both multi-item and single scales, including a global health status/quality of life (GHS/QoL) scale. Participants rate items on a four-point scale, with 1 as "not at all" and 4 as "very much." A change of 5 - 10 points is considered a small change. A change of 10 - 20 points is considered a moderate change.
Patient reported functioning per EORTC QLQ-CR29 in CRC patients Approximately 90 days from last dose; up to 5 years The EORTC QLQ CR-29 questionnaire consists of 29 items (Likert scale), with a response scale for each of them from 1 to 4, with the following structure: 1 = Not at All 2 = A little; 3 = Quite a Bit; 4 = Very much. The QLQ-CR29 has five functional and 18 symptom scales. It contains four subscales (urinary frequency (UF), blood and mucus in stool (BMS), stool frequency (SF), and body image (BI)) and 19 single items (urinary incontinence, dysuria, abdominal pain, buttock pain, bloating, dry mouth, hair loss, taste, anxiety, weight, flatulence, fecal incontinence, sore skin, embarrassment, stoma care problems, sexual interest (men), impotence, sexual interest (women), and dyspareunia). Scores can be linearly transformed to provide a score from 0 to 100. Higher scores represent better functioning on the functional scales and a higher level of symptoms on the symptom scales.
Patient reported functioning per EORTC QLQ-HN35 in HNSCC patients Approximately 90 days from last dose; up to 5 years The EORTC QLQ-HN35 is a 35-item, disease-specific module which assesses quality of life across multiple scales, including pain, swallowing, and senses.
The questionnaire has 35 Likert type questions in total and the evaluation is made by giving the score of None: 1, A little: 2, Quite: 3, A lot: 4.Patient reporting general health status per EORTC QLQ-CR29 in CRC patients Approximately 90 days from last dose; up to 5 years The EORTC QLQ CR-29 questionnaire consists of 29 items (Likert scale), with a response scale for each of them from 1 to 4, with the following structure: 1 = Not at All 2 = A little; 3 = Quite a Bit; 4 = Very much. The QLQ-CR29 has five functional and 18 symptom scales. It contains four subscales (urinary frequency (UF), blood and mucus in stool (BMS), stool frequency (SF), and body image (BI)) and 19 single items (urinary incontinence, dysuria, abdominal pain, buttock pain, bloating, dry mouth, hair loss, taste, anxiety, weight, flatulence, fecal incontinence, sore skin, embarrassment, stoma care problems, sexual interest (men), impotence, sexual interest (women), and dyspareunia). Scores can be linearly transformed to provide a score from 0 to 100. Higher scores represent better functioning on the functional scales and a higher level of symptoms on the symptom scales.
Patient reporting general health status per EQ-5D-5L Approximately 90 days from last dose; up to 5 years The EQ-5D-5L consists of EQ-5D descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems.
Patient reported functioning per EQ-5D-5L Approximately 90 days from last dose; up to 5 years The EQ-5D-5L consists of EQ-5D descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems.
Patient reporting general health status per EORTC QLQ-C30 Approximately 90 days from last dose; up to 5 years EORTC-QLQ-C30 is a 30-item subject self-report questionnaire composed of both multi-item and single scales, including a global health status/quality of life (GHS/QoL) scale. Participants rate items on a four-point scale, with 1 as "not at all" and 4 as "very much." A change of 5 - 10 points is considered a small change. A change of 10 - 20 points is considered a moderate change.
Patient reporting general health status per EORTC QLQ-BR23 in breast cancer patients Approximately 90 days from last dose; up to 5 years The EORTC-QLQ-BR23 includes functional scales (body image, sexual functioning, sexual enjoyment, and future perspective) and single item symptoms scales (systemic therapy side effects, breast symptoms, arm symptoms, and upset by hair loss). Questions use 4-point Likert scale (1 'Not at All' to 4 'Very Much'). Scores average and transformed to 0-100 scale. High score for functional scale=high/healthy level of functioning. High score for single item=high level of symptomatology/problems.
Trial Locations
- Locations (48)
Hospital 12 de Octubre
🇪🇸Madrid, Spain
Netherlands Cancer Institute
🇳🇱Amsterdam, Netherlands
Valkyrie Clinical Trials
🇺🇸Los Angeles, California, United States
University of California Los Angeles (UCLA) Medical Center
🇺🇸Los Angeles, California, United States
The Regents of the University of California, San Francisco
🇺🇸San Francisco, California, United States
University of Florida Health
🇺🇸Gainesville, Florida, United States
Moffitt Cancer Center
🇺🇸Tampa, Florida, United States
University of Illinois Cancer Center
🇺🇸Chicago, Illinois, United States
University of Iowa Hospitals and Clinics
🇺🇸Iowa City, Iowa, United States
Dana Farber Cancer Institute Brookline Avenue
🇺🇸Boston, Massachusetts, United States
START Midwest - Cancer & Hematology Centers of Western Michigan, PC
🇺🇸Grand Rapids, Michigan, United States
Rutgers Cancer Institute of New Jersey
🇺🇸New Brunswick, New Jersey, United States
Memorial Sloan Kettering Cancer Center
🇺🇸New York, New York, United States
University of Cincinnati Medical Center
🇺🇸Cincinnati, Ohio, United States
The Stefanie Spielman Comprehensive Breast Center
🇺🇸Columbus, Ohio, United States
Fox Chase Cancer Center
🇺🇸Philadelphia, Pennsylvania, United States
Sarah Cannon Research Institute - 25th Ave
🇺🇸Nashville, Tennessee, United States
MD Anderson Cancer Center
🇺🇸Houston, Texas, United States
South Texas Oncology And Hematology
🇺🇸San Antonio, Texas, United States
Medical College of Wisconsin
🇺🇸Milwaukee, Wisconsin, United States
Centre Jean Perrin
🇫🇷Clermont-Ferrand, Auvergne, France
Centre Georges Francois Leclerc
🇫🇷Dijon, Bourgogne Franche Comte, France
Institut Claudius Regaud, IUCT-Oncopole
🇫🇷Toulouse, Haute-Garonne, France
Begin Army Instruction Hospital
🇫🇷Saint-Mande, Ile De France, France
Gustave Roussy
🇫🇷Villejuif, Ile De France, France
Hopital Lyon Sud
🇫🇷Pierre-Benite, Lyon, France
Centre Antoine Lacassagne
🇫🇷Nice, Provence Alpes Cote dAzur, France
Institut Bergonie
🇫🇷Bordeaux, France
Centre Leon Berard (CLB) - Centre de Recherche en Cancerologie Lyon-Est (CRCL)
🇫🇷Lyon, France
Centre Hospitalier Universitaire (CHU) de Poitiers
🇫🇷Poitiers, France
Sheba Medical Center
🇮🇱Ramat Gan, Hamerkaz, Israel
Soroka University Medical Center
🇮🇱Be'er Sheva, Israel
Rambam Health Care Campus
🇮🇱Haifa, Israel
Shaare Zedek Medical Center
🇮🇱Jerusalem, Israel
Hadassah Medical Center
🇮🇱Jerusalem, Israel
Tel Aviv Sourasky Medical Center
🇮🇱Tel Aviv, Israel
Medpolonia Sp. z o.o.
🇵🇱Poznan, Wielkopolska, Poland
Dom Lekarski SA
🇵🇱Szczecin, Zach, Poland
Hospital General de Catalunya
🇪🇸Sant Cugat del Valles, Barcelona, Spain
Hospital Universitario Quiron Salud Madrid
🇪🇸Pozuelo de Alarcon, Madrid, Spain
Hospital Universitari Vall d'Hebron
🇪🇸Barcelona, Spain
Hospital Clinico San Carlos
🇪🇸Madrid, Spain
Hospital Universitario Fundacion Jimenez Diaz
🇪🇸Madrid, Spain
Hospital Clinico Universitario - University of Valencia
🇪🇸Valencia, Spain
Baskent Universitesi
🇹🇷Yuregir, Adana, Turkey
Dr. Abdurrahman Yurtaslan Ankara Onkoloji Egitim ve Arastirma Hastanesi
🇹🇷Ankara, Turkey
Istanbul University Cerrahpasa at Cerrahpasa Medical Faculty
🇹🇷Istanbul, Turkey
Istanbul Medeniyet University - Prof Dr Suleyman Yalcin Sehir Hospital
🇹🇷Istanbul, Turkey